AG-490 is a tyrosine kinase inhibitor of JAK2, EGFR, and Neu that belongs to the family of tyrphostins. In acute lymphoblastic leukemia studies the compound has been reported to inhibit JAK2 from B cell precursors. Additionally, AG-490 has been observed to block cytokine-induced activation of JAK2 in eosinophils and STAT3 activation in T cell lymphoma cells. Unlike other kinase inhibitors, AG-490 does not inhibit JAK1, Lck, Btk, Tyk2, Syk, Lyn, and Src. Research indicates that AG-490 inhibits IL-7 mediated proliferation. Inhibition of Jak kinase activity by AG-490 leads to lower levels of p85 phosphorylation and p-13 kinase activation. AG-490 is an inhibitor of JAK3.

June 21, 2017

prudect name : AG-490 is a tyrosine kinase inhibitor of JAK2, EGFR, and Neu that belongs to the family of tyrphostins. In acute lymphoblastic leukemia studies the compound has been reported to inhibit JAK2 from B cell precursors. Additionally, AG-490 has been observed to block cytokine-induced activation of JAK2 in eosinophils and STAT3 activation in T cell lymphoma cells. Unlike other kinase inhibitors, AG-490 does not inhibit JAK1, Lck, Btk, Tyk2, Syk, Lyn, and Src. Research indicates that AG-490 inhibits IL-7 mediated proliferation. Inhibition of Jak kinase activity by AG-490 leads to lower levels of p85 phosphorylation and p-13 kinase activation. AG-490 is an inhibitor of JAK3.
AG-490

Synonyms: CAS NO: 134036-52-5Molecular Formula: C₁₇H₁₄N₂O₃Molecular Weight: 294.30Purity: 98% minSolubility: In DMSOStorage: -20°C

1221186-53-3 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18496697